Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2026-06-02 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 93% confidence The document is a Form 6-K Current Report by a foreign private issuer filed under the Securities Exchange Act (the SEC heading, Form 6-K label, Rule 13a-16/15d-16 references). It contains a press release, not an annual or quarterly financial report, not an earnings release (no financial results), governance proxy, or management/Q&A transcript. It is a regulatory filing of miscellaneous content, falling under the fallback category for regulatory announcements. Therefore it should be coded as RNS.
2026-06-02 English
6-K
Capital/Financing Update Classification · 83% confidence The document is a Form 6-K report by a foreign private issuer describing the filing of a prospectus supplement to increase the maximum aggregate offering amount under an At-The-Market Offering Agreement (i.e., an equity financing arrangement). This is a direct update on the company’s capital raising/financing activity rather than a full annual or interim report, earnings release, or other category. Therefore it best fits the Capital/Financing Update category (CAP).
2026-05-27 English
424B5 - RedHill Biopharma Ltd. (0001553846) (Filer)
Share Issue/Capital Change Classification · 88% confidence The document is a Form 424(b)(5) prospectus supplement to an existing Form F-3 registration statement, providing updated terms and increased maximum aggregate offering amount for American Depositary Shares (ADSs). This is a formal SEC filing announcing and authorizing the issuance of new shares (ADSs) under an at-the-market offering agreement. It directly relates to share issuance/capital changes rather than a general earnings release or management discussion. Therefore, it fits the "Share Issue/Capital Change" category.
2026-05-07 English
6-K - RedHill Biopharma Ltd. (0001553846) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by RedHill Biopharma Ltd., a foreign private issuer. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Forms 10-K or 10-Q. The content includes a press release about clinical trial results and development updates for a pharmaceutical product (RHB-204). There are no financial statements or detailed financial performance data presented. The document is primarily a regulatory filing to disclose material information to investors and the SEC. It is not an annual report, earnings release, management discussion, or any other specific report type. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other categories.
2026-04-30 English
20-F - RedHill Biopharma Ltd. (0001553846) (Filer)
Annual Report FY 2025
2026-04-27 English
6-K - RedHill Biopharma Ltd. (0001553846) (Filer)
Annual Report Classification · 95% confidence The document is a Form 6-K filing by RedHill Biopharma Ltd., a foreign private issuer, submitted to the SEC. It includes a press release announcing the company's full-year 2025 financial results and operational highlights. The text contains detailed financial data for the year ended December 31, 2025, including revenues, expenses, net loss, assets, liabilities, and cash flows. It also discusses strategic transactions, partnerships, and R&D progress. The presence of comprehensive financial statements and analysis for a full fiscal year indicates this is an annual report type document. Although it is filed on Form 6-K (used by foreign private issuers to report material information), the content corresponds to an annual report covering full-year financial performance and operational highlights. Therefore, the appropriate classification is Annual Report (10-K equivalent for foreign issuers).
2026-04-27 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.